Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Basically, Dialysis Is Not Good Enough

Seth B. Furgeson and Isaac Teitelbaum
CJASN February 2013, 8 (2) 177-178; DOI: https://doi.org/10.2215/CJN.12781212
Seth B. Furgeson
University of Colorado School of Medicine, Aurora, Colorado
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isaac Teitelbaum
University of Colorado School of Medicine, Aurora, Colorado
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

In CKD patients, the daily imbalance between endogenous acid production and renal acid excretion gradually leads to worsening metabolic acidosis. Although serum bicarbonate typically reaches a stable nadir, there is accumulating evidence that mild metabolic acidosis in late-stage CKD may cause adverse clinical outcomes. Specifically, several recent trials have focused on the relationship between metabolic acidosis and the rate of progression of CKD. The randomized controlled trial conducted by de Brito-Ashurst et al. demonstrated that sodium bicarbonate therapy slowed renal deterioration and improved nutritional outcomes (1). Another randomized trial comparing sodium bicarbonate to either sodium chloride or placebo showed that sodium bicarbonate slowed the decline in kidney function (2). Along with other supportive animal data indicating that alkalinization is renoprotective (3), there is now reasonable evidence that correction of metabolic acidosis may preserve residual kidney function.

Because residual kidney function is an important predictor of survival in both hemodialysis (HD) and peritoneal dialysis (PD) patients, these data may also be germane to the ESRD population. Indeed, several small randomized controlled trials have supported the hypothesis that metabolic acidosis is deleterious to patients on dialysis as well as to those with earlier stages of CKD. In one study, Szeto et al. randomized PD patients with metabolic acidosis to treatment with either sodium bicarbonate tablets or placebo (4). Treatment was well tolerated and was associated with improvement in the subjective global assessment score and normalized protein nitrogen appearance rate. The treatment group also had fewer days of hospitalization. In another study, PD patients were randomized to two different lactate concentrations (35 mmol/L versus 40 mmol/L) in their dialysate. The patients receiving the high lactate dialysate had improved weight gain and arm circumference, as well as fewer hospitalization days (5).

Patients’ choices regarding dialysis modality are dictated by a number of factors, not least among which is the recommendation of their nephrologist. As nephrologists, educating patients about the risks and benefits of different dialysis modalities can be challenging. The major impediment to accurately comparing outcomes of PD and HD is the lack of randomized controlled trials. A large trial in which patients were randomly allocated to either HD or PD would answer many important questions. First, it would demonstrate whether either modality is associated with decreased mortality relative to the other. Importantly, it would also measure other outcomes such as infectious episodes and control of metabolic acidosis. However, because most patients have a firm preference regarding dialysis modality, performing a study of this nature has been extremely challenging due to difficulties with recruitment (6). To date, therefore, comparisons of outcomes obtained with the two dialysis modalities rely upon retrospective analysis of large databases. Whereas a large US cohort from the 1990s demonstrated a modest improvement in mortality during the first 2 years of PD and a late mortality benefit with HD (7), a more recent analysis of patients from the last decade showed equivalent mortality among HD and PD patients in the United States (8).

In this issue of CJASN, Vashistha et al. report interesting findings obtained from a retrospective analysis of patients who dialyzed under the auspices of one the large dialysis organizations in the United States between 2001 and 2006 (9). They examined outcomes of HD and PD patients with particular emphasis on the correction of metabolic acidosis. The large number of patients studied—over 10,000 on PD and 100,000 on HD—lends great strength and external validity to the data.

Unfortunately, the first major finding of this study is disheartening. Whereas patients on PD fared better than those on HD, metabolic acidosis was not well controlled in either patient population. Only 60% of HD patients and 75% of PD patients had time-averaged serum bicarbonate levels of 22 mEq/L or higher. In addition, the failure to correct acidosis is harmful: the authors then demonstrate that in both the HD and PD patient populations, there is an inverse relationship between serum bicarbonate levels and mortality, although it is more robust in HD patients than in PD patients. Mild metabolic acidosis (HCO3 between 20 and 24 mEq/L) was not associated with increased all-cause mortality in PD patients, whereas it was associated with approximately a 10% risk increase in HD patients. Severe metabolic acidosis (HCO3 <19 mEq/L) was associated with significant increases in mortality in both patient populations.

It is unclear why inadequate control of metabolic acidosis is so common in dialysis patients. The authors note the lack of clarity in international guidelines regarding serum bicarbonate. In the bone metabolism guidelines, the Kidney Disease Outcomes Quality Initiative does recommend bicarbonate levels >22 mEq/L for patients with CKD stages 3–5 (10). In the United States, the Centers for Medicare and Medicaid Services Quality Incentive Program has begun to partially link reimbursement with quality measures. Although delivered dialysis dose is one measure that will be rewarded, control of metabolic acidosis is not mentioned (11). Given the lack of emphasis on metabolic acidosis, it may not be surprising that a large number of both HD and PD patients do not achieve normal serum bicarbonate levels.

The other central finding by Vashistha et al. concerns the relatively worse outcomes seen on HD compared with PD (9). The authors propose several hypotheses to explain the higher prevalence of metabolic acidosis among HD patients. The higher base concentration of peritoneal dialysate may partially explain the difference. Furthermore, as with most studies comparing PD with HD, the possibility of bias exists. Despite controlling for comorbidities, the patients on PD may have been healthier or less likely to develop metabolic acidosis. Another limitation concerns the difference between the intermittent nature of HD and the more continuous nature of PD. Consequently, the authors compared true steady-state serum bicarbonate levels in PD patients with mean predialysis levels, the lowest obtained during the week, in HD patients. To minimize that discrepancy, and to more closely simulate mean steady-state serum bicarbonate values, the authors performed an analysis in which they added 3 mEq/L to the pre-HD bicarbonate concentration and obtained similar results. Although there are limitations regarding this comparison, this is a potentially novel finding.

In summary, Vashistha et al. highlight a potential deficiency in modern dialytic therapy by documenting inadequate control of metabolic acidosis (9). At present, assessment of dialysis adequacy continues to rely heavily on measurements of small solute clearance. This remains the case despite the fact that in both HD and PD, studies have shown no mortality benefit with increases in small solute clearance beyond those commonly obtained (12,13). In contrast, it appears from this study that improved control of metabolic acidosis does decrease mortality of patients on dialysis. Perhaps it is time to broaden the assessment of dialysis adequacy to include this important parameter; more study is needed.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Dialysis Modality and Correction of Uremic Metabolic Acidosis: Relationship with All-Cause and Cause-Specific Mortality,” on pages 254–264.

  • Copyright © 2013 by the American Society of Nephrology

References

  1. 1.↵
    1. de Brito-Ashurst I,
    2. Varagunam M,
    3. Raftery MJ,
    4. Yaqoob MM
    : Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20: 2075–2084, 2009
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Mahajan A,
    2. Simoni J,
    3. Sheather SJ,
    4. Broglio KR,
    5. Rajab MH,
    6. Wesson DE
    : Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78: 303–309, 2010
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Nath KA,
    2. Hostetter MK,
    3. Hostetter TH
    : Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 76: 667–675, 1985
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Szeto CC,
    2. Wong TY,
    3. Chow KM,
    4. Leung CB,
    5. Li PK
    : Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: A randomized placebo-control trial. J Am Soc Nephrol 14: 2119–2126, 2003
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Stein A,
    2. Moorhouse J,
    3. Iles-Smith H,
    4. Baker F,
    5. Johnstone J,
    6. James G,
    7. Troughton J,
    8. Bircher G,
    9. Walls J
    : Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 52: 1089–1095, 1997
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Korevaar JC,
    2. Feith GW,
    3. Dekker FW,
    4. van Manen JG,
    5. Boeschoten EW,
    6. Bossuyt PM,
    7. Krediet RT
    ; NECOSAD Study Group: Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: A randomized controlled trial. Kidney Int 64: 2222–2228, 2003
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Collins AJ,
    2. Hao W,
    3. Xia H,
    4. Ebben JP,
    5. Everson SE,
    6. Constantini EG,
    7. Ma JZ
    : Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 34: 1065–1074, 1999
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mehrotra R,
    2. Chiu YW,
    3. Kalantar-Zadeh K,
    4. Bargman J,
    5. Vonesh E
    : Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med 171: 110–118, 2011
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Vashistha T,
    2. Kalantar-Zadeh K,
    3. Molnar MZ,
    4. Torlén K,
    5. Mehrotra R
    : Dialysis modality and correction of uremic metabolic acidosis: Relationship with all-cause and cause-specific mortality. Clin J Am Soc Nephrol 8: 254–264, 2013
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1–S201, 2003
  11. 11.↵
    1. Fishbane S,
    2. Miller I,
    3. Wagner JD,
    4. Masani NN
    : Changes to the end-stage renal disease quality incentive program. Kidney Int 81: 1167–1171, 2012
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Eknoyan G,
    2. Beck GJ,
    3. Cheung AK,
    4. Daugirdas JT,
    5. Greene T,
    6. Kusek JW,
    7. Allon M,
    8. Bailey J,
    9. Delmez JA,
    10. Depner TA,
    11. Dwyer JT,
    12. Levey AS,
    13. Levin NW,
    14. Milford E,
    15. Ornt DB,
    16. Rocco MV,
    17. Schulman G,
    18. Schwab SJ,
    19. Teehan BP,
    20. Toto R
    ; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010–2019, 2002
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Paniagua R,
    2. Amato D,
    3. Vonesh E,
    4. Correa-Rotter R,
    5. Ramos A,
    6. Moran J,
    7. Mujais S
    ; Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307–1320, 2002
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 8 (2)
Clinical Journal of the American Society of Nephrology
Vol. 8, Issue 2
February 07, 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Basically, Dialysis Is Not Good Enough
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Basically, Dialysis Is Not Good Enough
Seth B. Furgeson, Isaac Teitelbaum
CJASN Feb 2013, 8 (2) 177-178; DOI: 10.2215/CJN.12781212

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Basically, Dialysis Is Not Good Enough
Seth B. Furgeson, Isaac Teitelbaum
CJASN Feb 2013, 8 (2) 177-178; DOI: 10.2215/CJN.12781212
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Should We Let Dialysis Patients Eat Their Fruits and Veggies?
  • Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease
  • APOL1 Kidney Risk Variants and Acute Kidney Injury in Those with COVID-19
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Dialysis Modality and Correction of Uremic Metabolic Acidosis: Relationship with All-Cause and Cause-Specific Mortality
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire